In this interview, Mitchell von Itzstein, MD, discusses the challenges of treating KRAS-mutant non-small cell lung cancer (NSCLC), the potential of selinexor in combination with docetaxel, and the need for further research to refine treatment strategies for this patient population....
You are reading this latest preprint version Background Pulmonary sarcomatoid carcinoma (PSC) is a rare, highly aggressive non-small cell lung cancer (NSCLC) subtype (0.1%–4% of lung malignancies)[3]. Clinically, it mainly affects smokers, with half diagnosed at advanced stages; pathologically, it...
KRAS is one of the most frequently mutated oncogenes in non-small cell lung cancer (NSCLC), particularly in lung adenocarcinoma, with mutation rates ranging Highlights • First comprehensive synthesis of monotherapy and combination strategies for KRAS G12C-mutant NSCLC, integrating latest clinical...
Lung cancer remains the leading cause of cancer-related morbidity and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases [1]. KRAS mutation is one of the most common driver alterations in NSCLC, especially in...
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyaluronidase alfa-pmph. The study targets the first-line treatment...
